LTA4H-IN-2 , CAS No.2851480-52-7

CAS: 2851480-52-7 Cat. No.: L1441609 Formula: C₂₀H₁₉FN₆O₂ Peso molecolare: 394.40

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Panoramica

LTA4H-IN-2 (compound (S)-2 ) is an orally active inhibitor of Leukotriene A4 Hydrolase , with an IC 50 of <3 nM.

Specifications

Condizioni di conservazione di stoccaggio

Store at -20°C

Spedito in

Ice chest + Ice pads

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Tipo di azione

INHIBITOR

Nomi e identificatori

• Peso molecolare: 394.40

Application Protocols

• Item-specific validated applications
  • Not specified for this item; no tested applications or recommended dilutions are provided. Refer to CoA/Spec Sheet.
• General guidance for small-molecule tool compounds
  • Prepare concentrated DMSO stocks under dry conditions. Filter if necessary (0.22 µm PTFE) to remove particulates.
  • For biochemical assays, build 10-point serial dilutions (3-fold) to establish concentration–response curves; include DMSO-only controls at matching percentages.
  • Monitor compound stability over the assay duration by LC or UV to detect degradation or adsorption losses.
  • For cell-based assays, confirm tolerated DMSO concentration and assess cytotoxicity independently of target engagement.
  • Record batch number, preparation date, and number of freeze–thaw cycles for data traceability.

Biological Roles

• Item-specific biological data
  • Target specificity, potency, and selectivity for LTA4H-IN-2 are not specified for this item; refer to primary literature or the CoA if available.
• LTA4H pathway context (literature/general knowledge)
  • Leukotriene A4 hydrolase (LTA4H) is a bifunctional zinc metalloenzyme that converts leukotriene A4 (LTA4) to leukotriene B4 (LTB4), a potent lipid mediator derived from arachidonic acid via the 5-LOX pathway.
  • LTA4H exhibits epoxide hydrolase activity responsible for LTB4 formation and an aminopeptidase activity implicated in peptide turnover; small molecules can differentially modulate these activities (literature reports).
  • Modulation of LTA4H is used as a research strategy to study eicosanoid signaling, neutrophil chemotaxis, and inflammatory biochemistry in cell and enzyme systems.
• Practical assay considerations (general)
  • Enzymatic assays typically monitor LTB4 formation by LC–MS/MS or ELISA, or follow substrate surrogates fluorometrically for aminopeptidase activity.
  • In cellular models, confirm on-target pathway effects by measuring LTB4 levels alongside orthogonal markers (e.g., 5-LOX products) to control for off-pathway perturbations.
  • Establish compound solubility and non-specific binding to plastic or serum proteins to ensure accurate concentration-response relationships.

Buffer Applications

• Not typically applicable
  • LTA4H-IN-2 is a discrete bioactive small molecule, not a buffering agent. It does not define a buffer system or pH range.
• Practical handling (general)
  • For biochemical assays, prepare stocks in DMSO and dilute into assay buffers (e.g., Tris, HEPES, phosphate) keeping final DMSO low to avoid perturbing enzyme activity.
  • Validate buffer composition (salt, pH, cofactors such as Zn2+ for metalloenzymes) independently of the compound to ensure robust assay performance.

Green Alternatives

• Context
  • As a discrete bioactive compound, “green alternatives” typically relate to handling solvents and formulation rather than replacing the molecule itself.
• Solvent and process considerations (general, literature-based)
  • Prefer DMSO over DMF/NMP for assay stocks due to lower toxicity and favorable environmental profile, while still achieving high solubility.
  • For preparative dissolution or cleaning, consider ethanol or isopropanol before resorting to chlorinated solvents; validate solubility first.
  • Minimize single-use plastics by aliquoting into reusable glass vials with PTFE-lined caps when feasible.
• Comparison (general)
  • DMSO vs DMF/NMP: DMSO offers broad solvency with better EHS characteristics; DMF/NMP may solubilize extremely polar/planar molecules but carry reproductive toxicity classifications.
  • Aqueous cosolvent systems (buffer + ≤1% DMSO) reduce VOC usage compared to purely organic media in assays.
• Waste minimization
  • Prepare only the volume needed for the experimental window; store aliquots at -20°C to extend shelf life and reduce premature disposal.

Pharmaceutical Uses

• Scope clarification
  • This product is provided strictly for research use only. It is not formulated as a drug, diagnostic, or excipient, and is not intended for human or veterinary use.
• Formulation context (general)
  • In preclinical research settings, small-molecule inhibitors may be formulated for in vitro or ex vivo studies in DMSO-based vehicles or aqueous buffers with minimal co-solvent; however, no item-specific formulation guidance is provided here.
• Regulatory note
  • No pharmacopeial monograph or excipient status is indicated for this item. For any GLP or regulated workflows, obtain batch documentation and perform independent qualification.

Physical Properties

• Item-specific properties (specifications)
  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Melting point: Not specified for this item; refer to CoA/Spec Sheet.
  • Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
  • Density: Not specified for this item; refer to CoA/Spec Sheet.
  • Solubility: Not specified for this item; refer to CoA/Spec Sheet.
  • LogP, pKa, refractive index, UV-Vis cutoff: Not specified for this item; refer to CoA/Spec Sheet.
• General expectations for small-molecule inhibitors (literature/general knowledge)
  • Many screening compounds are supplied as solids and reconstituted in anhydrous DMSO due to broad solvency for heteroaromatics and amide/urea motifs.
  • For aqueous use, co-solvent systems (e.g., DMSO ≤1–2% v/v plus buffer) or inclusion of minimal PEG or cyclodextrin are common (general practice). Always verify compatibility with your assay.
• Practical notes
  • If the CoA provides a melting range, use it to quickly assess identity/purity on receipt (capillary MP as a qualitative check).
  • Determine solubility empirically in your intended medium; begin with DMSO, then titrate aqueous buffer while monitoring for precipitation (light scattering or UV baseline drift).

Quality and Grades

• Item-specific grade/purity
  • Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
• How to interpret common grades (general guidance)
  • Screening library grade: Typically suitable for biochemical/cellular assays; supplier may report LC/MS identity and HPLC purity (e.g., ≥95% area) with water/residual solvent data. Verify with batch CoA.
  • Analytical reagent (AR) or ≥98% grade: Often used when off-target profiling or SAR requires minimal impurities.
  • HPLC grade (for solvents) vs compound purity: Note that “HPLC grade” refers to solvents, not bioactives. For small molecules, look for HPLC purity, LC/MS, NMR, and residual metals/solvents.
• Documentation to request/use
  • Batch-specific CoA including chromatogram, method, and detection wavelength.
  • Identity confirmation (LC/MS or HRMS) and, when available, NMR or elemental analysis.
  • Stability and retest date under specified storage (-20°C for this item).
• Practical QA tips
  • Upon receipt, perform a quick identity/purity check (orthogonal LC method) before committing to critical studies.
  • Track freeze–thaw cycles for DMSO stocks; aliquot to minimize degradation and water uptake.

Reaction and Applications

• Applicability to synthetic reactions
  • This product is a cataloged small-molecule inhibitor for research use and is not typically employed as a synthetic reagent or solvent.
  • No named-reaction roles (e.g., coupling partner, catalyst, oxidant) are defined for this item based on available data.
• Recommended uses (per category; general)
  • Suitable for assembling bioactive screening panels, target validation studies, and mechanistic enzymology where LTA4H biology is investigated (see Biological Roles). Specific potency/selectivity for this item is not provided here.
• If you intend to derivatize
  • Without structural information, no guidance on functional handles can be given. Obtain the structure before planning prodrug, photoaffinity, or probe synthesis.
• Documentation reminder
  • For application-specific suitability (biochemical vs cellular), consult the CoA/SDS and perform pilot assays to establish solubility, stability, and non-specific binding in your matrices.

Reaction Conditions

• Not applicable as a reagent
  • No item-specific reaction conditions are defined because this compound is not supplied for use as a catalyst, reagent, or solvent.
• General note for biochemical testing
  • For enzyme assays involving LTA4H, typical buffers are near neutral pH with appropriate ionic strength and Zn2+ availability; temperature control (e.g., 25–37°C) and short incubation times help preserve substrate integrity. These parameters should be optimized per literature methods and are not item-specific.

Safety and Handling

• Item-specific hazard data
  • Signal word: Not specified for this item; refer to SDS.
  • H-statements: Not specified for this item; refer to SDS.
  • GHS classification/pictograms: Not specified for this item; refer to SDS.
• General laboratory precautions (defer to SDS for authoritative guidance)
  • Handle in a chemical fume hood with standard PPE: lab coat, nitrile gloves, and splash goggles. Avoid inhalation of dust/aerosols and contact with skin/eyes.
  • Prevent environmental release; collect waste in appropriate organic waste streams.
• Incompatibilities and stability (general)
  • Small-molecule inhibitors can include electrophilic or base-/acid-labile motifs. Until specifics are known, avoid strong oxidizers/reductants, strong acids/bases, and prolonged light/heat exposure.
  • Hygroscopicity and photosensitivity are compound-dependent; store tightly sealed under inert headspace if possible.
• First aid (overview; consult SDS)
  • Skin/eye contact: Rinse with water for at least 15 minutes; remove contaminated clothing; seek medical attention if irritation persists.
  • Inhalation: Move to fresh air; obtain medical attention if symptoms occur.
  • Ingestion: Rinse mouth; do not induce vomiting; seek medical attention.
• Spill/accidental release
  • Avoid dust formation. Cover with inert absorbent, collect mechanically, and dispose per institutional and local regulations.

Solvent Selection

• Item-specific solvent preferences: Not specified for this item; refer to CoA/Spec Sheet.
• General strategy for small-molecule inhibitors
  • Primary solvent: Anhydrous DMSO is the default for reconstituting diverse heteroaromatic/amide-rich compounds due to high polarity and broad solvency.
  • Alternative aprotic polar solvents: DMF, NMP (use with caution in bioassays due to cytotoxicity), and acetone for some neutral compounds.
  • Co-solvent approaches: Prepare a concentrated DMSO stock (e.g., 10–50 mM; general practice) and dilute into aqueous assay buffer keeping final DMSO ≤0.1–1% v/v to limit assay interference.
  • Surfactant-assisted solubilization: For hydrophobic scaffolds, a small amount of nonionic surfactant (e.g., 0.01% Tween-20) or 2-hydroxypropyl-β-cyclodextrin can help maintain clarity (general literature guidance).
• Decision points and troubleshooting
  • If precipitation occurs on dilution, add the DMSO stock last with vigorous mixing or sonicating briefly; consider warming to 37°C.
  • Check UV absorbance of solvent system at assay wavelength to avoid baseline artifacts.
  • For long incubations, verify compound stability in the chosen medium (time-course LC) to rule out hydrolysis or oxidation.

Storage and Reconstitution

• Item-specific storage and shipping
  • Storage conditions: Store at -20°C.
  • Shipped in: Ice chest + ice pads.
• Container and handling (general best practices)
  • Keep tightly closed in the original container with desiccant if provided. Protect from light and moisture. Allow vials to equilibrate to room temperature in a desiccator before opening to minimize condensation.
• Reconstitution (general guidance; not item-specific)
  • If supplied as a solid: Dissolve in anhydrous DMSO to prepare a concentrated stock (commonly 10–50 mM for screening use). Mix gently or sonicate briefly to aid dissolution.
  • If supplied as a solution: Verify concentration and solvent on the label/CoA before dilution. Avoid repeated freeze–thaw by preparing single-use aliquots.
  • For aqueous working solutions: Dilute the DMSO stock into buffer with vigorous mixing to achieve the desired final concentration while keeping DMSO low (≤0.1–1% v/v, general practice). Inspect for precipitation or turbidity.
• Stability considerations
  • Track freeze–thaw cycles; store aliquots at -20°C. Reassess purity by LC after extended storage. Discard solutions showing precipitation, discoloration, or significant purity loss.
• Documentation
  • Record lot number, preparation details, and storage history to support reproducibility and data integrity.

Structure and Identity

• Item-specific identifiers
  • SKU: L1441609
  • Product name: LTA4H-IN-2
  • CAS: 2851480-52-7
  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• Structural description
  • Item-specific structural features are not provided in the current product data.
  • The name suggests a small-molecule inhibitor designed to target leukotriene A4 hydrolase (LTA4H); however, without a structure we cannot describe ring systems, heteroatoms, or stereocenters for this exact item.
• Guidance
  • If you require definitive structural attributes (functional groups, 2D/3D depiction), please request the CoA/Spec Sheet or structural file (SDF/Mol) for this specific batch.
  • For database registration and ELN, use the provided CAS and SKU; add structural fields once the supplier CoA is received.

Synthetic Utility

• Not typically a synthetic building block
  • As a named inhibitor, LTA4H-IN-2 is intended for use as a bioactive probe rather than as a reagent, monomer, or intermediate in organic synthesis.
• If derivatization is contemplated (general guidance)
  • Secure the exact structure and identify modifiable positions before planning linkers (biotin/fluorophore), photoaffinity groups, or isotopic labels.
  • Evaluate how substitutions affect physicochemical properties (cLogP, pKa, TPSA) to maintain solubility and permeability profiles suitable for your assays.
  • Orthogonal protection and late-stage diversification strategies (e.g., SuFEx, click chemistry) require knowledge of available functional handles; consult structural data first.

Target Specificity

• Item-specific data
  • Target, Ki/IC50, and selectivity panel results for LTA4H-IN-2 are not specified for this item; refer to CoA/Spec Sheet or primary literature.
• General context (literature)
  • LTA4H is a Zn2+-dependent epoxide hydrolase/aminopeptidase. Many inhibitors coordinate the catalytic Zn2+ or occupy the hydrophobic pocket proximal to the active site, but no binding mode is asserted for this specific item.
• Recommendation
  • Confirm target engagement via orthogonal assays (biochemical IC50 and cellular pathway readouts) and include counterscreens against related epoxide hydrolases or metalloproteases where relevant.